CORT vs DASH · P/E 199, rev $675.0M vs P/E 76, rev $13.72B
Corcept Therapeutics Incorporated (CORT) versus DoorDash, Inc. Class A Common Stock (DASH) — a side-by-side from cached financials, not a winner call.
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
DoorDash, Inc. Class A Common Stock (DASH) is a internet retail company listed on US.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
Latest reported DASH revenue for 2025-12-31 was $13.72B. Net income was $935.0M. Revenue was up 27.9% from 2024-12-31 to 2025-12-31. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. DASH currently screens at market cap $69.41B and trailing P/E 75.9.
Not investment advice. Open the CORT and DASH stock pages for the full models.
Not investment advice.